DNQX

DNQX is a competitive antagonist of the AMPA receptor, a type of ionotropic glutamate receptor. It is commonly used in research to help understand the function of these receptors, and has also been used in the study of neurodegenerative diseases and conditions such as epilepsy and ischemia.

Chemistry

DNQX, or 6,7-dinitroquinoxaline-2,3-dione, is a quinoxalinedione compound. It is a yellow solid at room temperature. It is soluble in DMSO and ethanol, but not in water.

Mechanism of action

DNQX acts as a competitive antagonist at the AMPA receptor, meaning it binds to the same site as the natural ligand, glutamate, but does not activate the receptor. This prevents glutamate from binding and activating the receptor, effectively blocking the receptor's function.

Uses in research

DNQX is commonly used in neuroscience research to help understand the function of AMPA receptors. By blocking these receptors, researchers can study their role in various processes in the nervous system.

In addition, DNQX has been used in the study of neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. It has also been used in research on conditions such as epilepsy and ischemia, where overactivation of glutamate receptors can lead to cell death.

Safety

As with any chemical, DNQX should be handled with care. It can cause eye, skin, and respiratory irritation. It is not intended for human consumption.

See also

• AMPA receptor
• Glutamate receptor
• Neurodegenerative diseases
• Epilepsy
• Ischemia

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia

References

<references />

External links

• PubChem Compound Summary for DNQX
• The use of DNQX in neuroscience research

DNQX

• 
  DNQX
• 
  DNQX molecule spacefill